Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
Protein expression was detected by SuperSignal West Pico Chemiluminescent substrate (Thermo, Waltham, MA, USA) and Fujifilm LAS-3000 (Fujifilm, Tokyo, Japan)
So the medications are for weight loss
The intravitreal injection of lanosterol nanoparticles rescues lens structure collapse at an early stage in shumiya cataract rats
Andrew Adams of Eli Lilly giving a keynote talk at the 12th ARDD in Copenhagen The atmosphere in the Grand Hall was electric